A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm, open label, non-randomized, phase II study designed to
investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in
patients with relapsed/refractory Waldenström Macroglobulinemia (R/R MW).